Research programme: protozoan infection and tuberculosis therapeutics - Broad Institute/EisaiAlternative Names: Chagas disease therapeutics - Broad Institute/Eisai; Malaria therapeutics - Broad Institute/Eisai; Protein synthesis inhibitors - Broad Institute/Eisai
Latest Information Update: 19 Sep 2014
At a glance
- Originator Broad Institute; Eisai Co Ltd
- Class Small molecules
- Mechanism of Action Protein synthesis inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Chagas disease; Malaria; Protozoan infections; Tuberculosis